Genmab

	15/5 09:08 af Sukkeralf	Could we get phase III data in amyloidosis with sc dara as a late breaker at EHA instead of ASCO?
	15/5 09:04 af Sukkeralf	or maybe even in the ASCO weekend
	15/5 09:02 af Sukkeralf	I still hope we will get that epcorita mab deal before ASCO - so my guess is either this weekend or next weekend. I would be nice to get that extra attention at ASCO. Maybe even more important in these Corona times so Genmab and Partner can keep this project moving as fast as possible
	15/5 08:40 af E L	Daratumumab treatment in heavely pre-treated immunoglobulin light chain amyloidosis (link)
	15/5 07:19 af bibob	(link)
	15/5 07:15 af bibob	ASCO: J&J 's anti - BCMA CAR-T improving with time sweeps Multiple Myeloma aside. (link)
	15/5 07:05 af bibob	GMAB US. Luk i 28,59 $. = 1981,28 kurs 6,93 $ :-)
	15/5 07:01 af bibob	God morgen. :-)
	15/5 06:11 af Plimsoller	God morgen :-)
	15/5 01:46 af gentogen	Inspireret af EL 20:14 tjekkede jeg lige igen. 2796811. Det er ganske pænt...
	15/5 00:19 af sponsor	Så kom da med den fredagsnyhed , så vi kan få skiftet sokker! ;-)
	14/5 23:04 af bikube	Kommer der også milestone til Gen.
	14/5 23:03 af bikube	Halozyme får $15M i milestone for første salg af Dara sc fra Janssen, siger Seeking.
	14/5 22:00 af Solsen	Legend IPO (link)
	14/5 21:40 af Parasitism	Der er bare nogen, som har glemt at informere Halo om at USA er i plus ????
	14/5 21:16 af Sukkeralf	(link)
	14/5 20:16 af Darvin	US vender også som “ventet” efter 2,5 dag :-)
	14/5 20:14 af E L	second day of over 2 mio ADS in the US
	14/5 20:05 af Solsen	Just like waiting for christmas. Not many days before we se the partner.
	14/5 18:32 af E L	some notable Asco presentations; includes epco (link)
	14/5 18:21 af E L	;-)
	14/5 17:49 af nohope	I may not be right about everything, but in this case I´m sure I´m right
	14/5 17:42 af Solsen	Until now nohope are right - we all die.
	14/5 17:31 af Bulder	It's almost like a cure. You can live for so many years with MM, that you'll die from age anyway.

	14/5 17:30 af Solsen	EPCORITAMAB has show its value today !
	14/5 17:29 af Solsen	You are so right !
	14/5 17:28 af Bulder	Nevertheless it is very positive,that in the late lines, when all other options are used, there still is a possibility to have a sCR.
	14/5 17:28 af Solsen	And thats where the big money are.
	14/5 17:27 af Solsen	Perhaps not many but to many to first, second and perhaps third line.
	14/5 17:25 af Solsen	With Car-T you manipulate with the immune system in a way that you dont have 100% control. Some pts just suddenly die.
	14/5 17:24 af E L	yea, think so too. Jan said that from the beginning, didn't he. The market clearly overshot in car-t optimism when it first came out, where in this chat most have been relatively negative
	14/5 17:23 af Solsen	I still think its for the last choise - due to sideeffects (possible grade 5) and price.
	14/5 17:20 af Solsen	yes
	14/5 17:19 af E L	you mean the JNJ car-t?
	14/5 17:18 af Solsen	At the moment its no competitor to dara. I think we now can say no thread to dara the next 5 years either from Takeda or JNJ.
	14/5 17:18 af E L	"CD38-knockout NK cells, which have been designed in attempt to prevent fratricide and enhance the activity of daratumumab" (link)
	14/5 17:15 af E L	yes, it is getting a bit more press than the bcma/cd3. but i am glad JNJ feels comfortable showing it out now, had been so quiet about it
	14/5 17:13 af Bulder	Heavily pretreated pts
	14/5 17:11 af Bulder	Janssens bcma car-t har 100% ORR, 86% sCR men eet dødsfald pga CRS. (link)
	14/5 16:00 af E L	A PHASE 1 STUDY OF TECLISTAMAB, A HUMANIZED B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) (link)
	14/5 16:00 af E L	hang on, one more by Mrs Mateos even:
	14/5 15:59 af GeorgeBest	tak Pensionisten - 15:14
	14/5 15:48 af E L	DUOHEXABODY®-CD37 SHOWS POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL B-CELL LYMPHOMA MODELS IN VITRO AND IN VIVO (link)
	14/5 15:48 af E L	lol. let's put the DuoHexa up also:
	14/5 15:48 af Helge Larsen/PI-redaktør	Tak for links E L.
	14/5 15:47 af Helge Larsen/PI-redaktør	:-D
	14/5 15:47 af E L	ok Genmab just send the mail with EHA stuff that is easier...
	14/5 15:42 af E L	EVALUATION OF PHARMACODYNAMIC BIOMARKERS OF EPCORITAMAB (GEN3013; CD3XCD20): RESULTS FROM A PHASE 1/2 DOSE-ESCALATION STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (link)
	14/5 15:42 af E L	SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: DOSE-ESCALATION DATA FROM A PHASE 1/2 TRIAL (link)
	14/5 15:30 af E L	SUPERIOR ANTI-TUMOR ACTIVITY OF HEXABODY®-CD38 IN PRECLINICAL MODELS OF MULTIPLE MYELOMA, B CELL LYMPHOMA AND ACUTE MYELOID LEUKEMIA (link)